Primary biliary cirrhosis of the liver and sarcoidosis have certain clinical and histomorphological features in common. It has been inferred from this that when the two diseases occur together its assignment to the one or other is not possible and a new nosological entity is to be assumed. Two own cases are described. Both had primary biliary cirrhosis, sarcoidosis developing 12 and 13 years, respectively, after the former had been first diagnosed. The findings in this cases speak against the two diseases constituting a nosological entity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1068198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Suboptimal Response in Primary Biliary Cholangitis Treatment.
Gastroenterol Hepatol (N Y)
November 2024
Lily and Terry Horner Chair in Autoimmune Liver Disease Research Professor of Medicine, Division of Gastroenterology and Hepatology University of Toronto The Autoimmune and Rare Liver Disease Programme Toronto General Hospital Toronto, Ontario, Canada.
Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic review and meta-analysis.
Front Endocrinol (Lausanne)
January 2025
Department of Orthopedics Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Background: Mendelian randomization is believed to attenuate the biases inherent in observational studies, yet a meta-analysis of Mendelian randomization studies in osteoporosis has not been conducted thus far. This study aims to evaluate the connection between potential causal factors and the risk of osteoporosis by synthesizing evidence from Mendelian randomization studies.
Methods: The databases PubMed, Web of Science, and Embase were systematically searched for Mendelian randomization studies investigating factors influencing osteoporosis up to May 2024.
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFObjectives: E-learning with video content was created to improve trainees' biliary cannulation techniques; this study aimed to evaluate its educational effect prospectively.
Methods: E-learning program was conducted using videos demonstrating biliary cannulation for 24 papillae, targeting trainees with 2-6 years of experience in endoscopic retrograde cholangiopancreatography. Ten consecutive cases of biliary cannulation for native papillae performed by trainees were prospectively assessed before and after the e-learning, respectively.
Surgical and oncological implications of the presence of hepatic artery anatomical variations in patients undergoing pancreaticoduodenectomy: a single center experience.
Updates Surg
January 2025
Pancreatic and Endocrine Surgical Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
The presence of an aberrant right hepatic artery (a-RHA) could influence the oncological and postoperative outcomes after pancreaticoduodenectomy (PD). A comparative study was conducted, including patients who underwent PD with a-RHA or with normal RHA anatomy. The primary endpoints were R1 resection in all margins (pancreatic, anterior, posterior, superior mesenteric artery, and portal groove), overall survival (OS), and disease-free survival (DFS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!